AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

UK Regulator Asked To Get On With Review; US Unlikely To Accept Data

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.

Jenner Institute by John Cairns
UK regulator will review core data on the AZD1222 vaccine • Source: John Cairns for Jenner Institute

AstraZeneca and Oxford University are set to sideline the "lucky mistake" data which boosted the Phase III results of their COVID-19 vaccine earlier this week, after facing criticism about how the study was performed and doubts about the robustness of the interim data.

The partners are now emphasizing the lower 62% efficacy level from their trials in patients who received both high doses...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet